Details for New Drug Application (NDA): 022083

✉ Email this page to a colleague

NDA 022083 describes EXELON, which is a drug marketed by Novartis and Sandoz and is included in three NDAs. It is available from two suppliers. Additional details are available on the EXELON profile page.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.

Summary for 022083

Tradename:	EXELON
Applicant:	Sandoz
Ingredient:	rivastigmine
Patents:	0

Pharmacology for NDA: 022083

Mechanism of Action	Cholinesterase Inhibitors

Medical Subject Heading (MeSH) Categories for 022083

Cholinesterase Inhibitors
Neuroprotective Agents

Suppliers and Packaging for NDA: 022083

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083	NDA	Novartis Pharmaceuticals Corporation	0078-0501	0078-0501-15	30 PATCH in 1 CARTON (0078-0501-15) / 24 h in 1 PATCH (0078-0501-61)
EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083	NDA	Novartis Pharmaceuticals Corporation	0078-0502	0078-0502-15	30 PATCH in 1 CARTON (0078-0502-15) / 24 h in 1 PATCH (0078-0502-61)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	FILM, EXTENDED RELEASE;TRANSDERMAL			Strength	4.6MG/24HR
Approval Date:	Jul 6, 2007	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	FILM, EXTENDED RELEASE;TRANSDERMAL			Strength	9.5MG/24HR
Approval Date:	Jul 6, 2007	TE:	AB	RLD:	Yes

Profile for product number 005

Active Rx/OTC/Discontinued:	RX	Dosage:	FILM, EXTENDED RELEASE;TRANSDERMAL			Strength	13.3MG/24HR
Approval Date:	Aug 31, 2012	TE:	AB	RLD:	Yes

Expired US Patents for NDA 022083

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	6,316,023	⤷ Subscribe
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	4,948,807	⤷ Subscribe
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	5,602,176	⤷ Subscribe
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007	4,948,807	⤷ Subscribe
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	6,316,023	⤷ Subscribe
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	6,335,031	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.